HutchMed Completes USD 1.295 Billion Licensing Transaction with GSK for HMPL‑A830 – First‑in‑Class KRAS‑Inhibitor ATTC Targets EGFR‑Expressing Tumors Globally

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced the completion of the transaction under its exclusive development and license agreement with GlaxoSmithKline (“GSK”), granting a subsidiary of GSK the exclusive rights to develop and commercialize HMPL‑A830 — a first‑in‑class antibody‑targeted targeted conjugate (ATTC) — globally outside of Greater China, for a total deal value of up to USD 1.295 billion.

Transaction Snapshot

Drug Profile & Mechanism of Action

• Modality: HMPL‑A830 is a first‑in‑class antibody‑targeted targeted conjugate (ATTC) — a next‑generation conjugate platform pairing antibody‑guided delivery with a small‑molecule targeted payload.
• Payload: A highly selective and potent small‑molecule KRAS (Kirsten rat sarcoma) inhibitor, conjugated to the antibody backbone.
• Targeting Vector: An anti‑EGFR (epidermal growth factor receptor) antibody that directs the conjugate to tumors with EGFR expression.
• Dual‑Pathway Blockade: By delivering the KRAS inhibitor directly to EGFR‑expressing tumors, HMPL‑A830 simultaneously blocks both the EGFR and KRAS signaling pathways — two central drivers of tumor growth and resistance in cancers including colorectal, head and neck, and other EGFR‑dependent malignancies.
• Design Goals: The conjugate architecture is intended to enhance efficacy, durability, and tolerability — concentrating KRAS inhibition at the tumor while limiting systemic exposure and the dose‑limiting toxicities associated with free small‑molecule KRAS inhibitors.
• KRAS Legacy: KRAS, long considered “undruggable,” has become one of oncology’s hottest targets following allele‑specific inhibitor breakthroughs; HMPL‑A830 pursues the distinct strategy of pan‑tumor, antibody‑directed KRAS payload delivery.

Market Impact & Outlook

• Deal Completion: Closing of the transaction finalizes the September 2026 agreement, securing the up‑to‑USD 1.295 billion economic framework and transferring ex‑Greater China rights to GSK’s subsidiary for downstream development and commercialization.
• Near‑Term Execution: HutchMed retains the global lead on the Phase I program, preserving clinical control during the value‑inflection stage before GSK assumes subsequent development — a structure that positions HutchMed to generate data while GSK industrializes the asset.
• Greater China Upside: Retaining rights in Mainland China, Hong Kong, Macau and Taiwan gives HutchMed full commercial participation in one of the world’s largest oncology markets.
• Big Pharma Validation: A billion‑dollar‑scale partnership with GSK on a first‑in‑class ATTC underscores both external validation of the KRAS‑conjugate platform and HutchMed’s emergence as a global licensor of novel modalities.
• Disclosures: Upfront payment, milestone structure breakdown, royalty rates, and Phase I timeline were not disclosed in the announcement.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, Phase I program execution, regulatory pathway, and commercialization expectations for HMPL‑A830 under the HutchMed–GSK collaboration. Actual results may differ materially due to risks including early‑phase clinical outcomes, GSK development decisions, regulatory review timelines, competitive dynamics in the KRAS and EGFR therapeutic spaces, and milestone achievement. Completion of a licensing transaction does not guarantee eventual approval or commercial success.-Fineline Info & Tech